Log In
BCIQ
Print this Print this
 

GB232

  Manage Alerts
Collapse Summary General Information
Company Walvax Biotechnology Co. Ltd.
DescriptionBiosimilar of adalimumab
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of ActionTumor necrosis factor (TNF) alpha inhibitor; Antibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard Indication Autoimmune (unspecified)
Indication DetailsTreat autoimmune diseases
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/10/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today